Massih tayebi biography templates

Mark W. Womack is an organization builder with a track record of delivering unprecedented growth and profit in every role.

Mark is BioCina’s Chief Executive Officer, and in his first 9 months at the helm he led BioCina to a % YOY increase in sales and a % YOY increase in revenue.

On February 1, , he was also appointed to the Board of Directors for both NovaCina and LumaCina.

Bridgewest group

In January of , BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufacturing. The combined company will retain the BioCina name and Mark is continuing as CEO.

Prior to BioCina, as CEO of KBI Biopharma and Selexis SA, Mr.

Womack led the company to a run rate of over a 30% YOY revenue increase in only 6 months. Previous to that, as CEO of Stelis Biopharma, he led Stelis to build and qualify a state-of-the-art vaccine facility in record time, while also generating over $M in new sales.

Preceding Stelis, as